Výsledky vyhledávání

Impact of different light colors in behavior, welfare parameters and growth performance of Fayoumi broiler chickens strain

Autor: S. N. Enas, M. H. Hesham, A. H. El Shereen

Publikováno v: Journal of the Hellenic Veterinary Medical Society. 69:951

Light is considered one of the most managerial factors affecting poultry well-being. Therefore, the current study was conducted to investigate the effects of different light colors in behaviour, welfare and growth performance of Fayoumi chickens. A t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::555920d524355613a0c2e7f51907351a
https://doi.org/10.12681/jhvms.18017

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Untitled]

Autor: M. L. Cloud, N. Enas, T. J. Humphries, S. Bassion, The Rabeprazole Study Group

Publikováno v: Digestive Diseases and Sciences. 43:993-1000

Rabeprazole, a new proton pump inhibitor, wasstudied in patients with acid-pepticrelated diseases(duodenal ulcer, gastric ulcer, GERD) in threeplacebo-controlled, double-blind, randomized clinicaltrials. Men and women over the age of 18 were enrolled

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::38f928d5359252fc4216e786e6728fbe
https://doi.org/10.1023/a:1018822532736

Zobrazit plný text záznamu

Akademický článek

DETECTION OF MORGANELLA MORGANII IN FROZEN MACKEREL VIA MULTIPLEX PCR RECOGNITION AND ASSIMILATION.

Autor: MOHAMED, ESRAA MARZOUK¹ esraamarzouk67@gmail.com, ABD-EL-MALEK, ASHRAF MOHAMED², ALI, WALEED SENOSY³, ZAKI, RANIA SAMIR¹

Publikováno v: Assiut Veterinary Medical Journal. Jul2024, Vol. 70 Issue 182, p106-113. 8p.

Zobrazit plný text záznamu

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas

Autor: W. L. Vervenne, D. A. Richards, H Oettle, N. Enas, James P. Thomas, Muhammad Wasif Saif, C. Visseren-Grul, G. Spitzer

Publikováno v: Cancer journal (Sudbury, Mass.), 15(4), 339-343. Lippincott Williams and Wilkins

Background: LY293111 (LY) is a novel oral anticancer agent with leukotriene B 4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties, producing promising results alone and in combination with gemcitabine in panc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaffa8f9f2e3ea9ec8d8dff0cf118574
https://pure.amc.nl/en/publications/randomized-doubleblind-phase-ii-trial-comparing-gemcitabine-plus-ly293111-versus-gemcitabine-plus-placebo-in-advanced-adenocarcinoma-of-the-pancreas(469ff4d2-0147-4ce4-b90f-131a89a7ecfc).html

Zobrazit plný text záznamu

Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients

Autor: Antonio Llombart-Cussac, Moïse Namer, José Baselga, V. Guillem-Porta, P. Vodvarka, Lubos Petruzelka, Meritxell Bellet, Eva Carrasco, K. Krejcy, M. Kuta, Pierre Kerbrat, L. Kayitalire, N. Enas, Ana Lluch

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 14(9)

Background This randomized, double-blind, phase II study assessed two doses of the selective estrogen receptor modulator arzoxifene in women with advanced breast cancer. The primary end point was to choose the best of two doses of arzoxifene based on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf2c3cf4e844f46b99d66c821b1cfd91
https://pubmed.ncbi.nlm.nih.gov/12954577

Zobrazit plný text záznamu

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

Autor: M L, Cloud, N, Enas, T J, Humphries, S, Bassion

Publikováno v: Digestive diseases and sciences. 43(5)

Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials. Men and women over the age of 18 were enr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d65ed104202a6b1c58ce8a3ac6c32057
https://pubmed.ncbi.nlm.nih.gov/9590413

Zobrazit plný text záznamu

Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study Group

Autor: M L, Cloud, N, Enas, W W, Offen

Publikováno v: Clinical pharmacology and therapeutics. 52(3)

To determine if 150 mg nizatidine twice daily or 300 mg nizatidine at bedtime are similarly effective and to compare each dose with placebo in healing benign gastric ulcers and relieving peptic ulcer symptoms.This study was a randomized, double-blind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8bac445749987f179d702aea9b4a8312
https://pubmed.ncbi.nlm.nih.gov/1526089

Zobrazit plný text záznamu

Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas

Autor: W. L. Vervenne, James P. Thomas, Helmut Oettle, N. Enas, G. Spitzer, Muhammad Wasif Saif, A. Weitzman, C. Visseren-Grul, D. A. Richards

Publikováno v: Journal of Clinical Oncology. 23:4092-4092

4092 Background: LY293111 (LY) is a novel oral anticancer agent with known leukotriene B4 receptor antagonist and peroxisome proliferator acvtivated receptor [PPAR] gamma agonist properties, that s...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66b2c48a1dc096586b8a58ea1b1b1f9e
https://doi.org/10.1200/jco.2005.23.16_suppl.4092

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání